Study design
The study design and methods have been published previouslyA single dose level of trofinetide was tested using weight-based dosing to achieve the target exposure identified based on the results of the previous phase 2 studyThe study included a screening period of ≤3 weeks, a 12-week double-blind treatment period and a 30-day safety follow-up for participants who did not continue into the open-label extension study (